Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 1, doi. 10.1002/pst.402
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2011 AND VI 10 AND IP 1
Results: 17
1
2
Potential surrogate endpoints in cancer research - some considerations and examples.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 34, doi. 10.1002/pst.406
- By:
- Publication type:
- Article
3
Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 70, doi. 10.1002/pst.417
- By:
- Publication type:
- Article
4
Commentary: Professional responsibilities.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 82, doi. 10.1002/pst.428
- By:
- Publication type:
- Article
5
Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 8, doi. 10.1002/pst.398
- By:
- Publication type:
- Article
6
Making available information from studies sponsored by the pharmaceutical industry: some current practices.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 60, doi. 10.1002/pst.430
- By:
- Publication type:
- Article
7
Commentary.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 83, doi. 10.1002/pst.441
- By:
- Publication type:
- Article
8
Effects of unstratified and centre-stratified randomization in multi-centre clinical trials.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 50, doi. 10.1002/pst.412
- By:
- Publication type:
- Article
9
Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 80, doi. 10.1002/pst.427
- By:
- Publication type:
- Article
10
The impact of period effects on dose level contrasts in alternating cross-over designs for first-time-in-human studies.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 45, doi. 10.1002/pst.409
- By:
- Publication type:
- Article
11
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 3, doi. 10.1002/pst.397
- By:
- Publication type:
- Article
12
Estimating time to steady state using the effective rate of drug accumulation.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 27, doi. 10.1002/pst.404
- By:
- Publication type:
- Article
13
Handbook of regression and modeling: applications for the clinical and pharmaceutical industries Paulson DS (2007) ISBN 157444610X; 520 pages; £57.99, $104.95 Chapman & Hall/CRC;.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 85, doi. 10.1002/pst.370
- By:
- Publication type:
- Article
14
Confirmatory analysis for phase III population pharmacokinetics.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 14, doi. 10.1002/pst.403
- By:
- Publication type:
- Article
15
Graphical displays for clarifying how allocation ratio affects total sample size for the two sample logrank test.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 40, doi. 10.1002/pst.407
- By:
- Publication type:
- Article
16
PSI's pharmaceutical statistics journal club.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. iii, doi. 10.1002/pst.487
- By:
- Publication type:
- Article
17
The potential for bias in reporting of industry-sponsored clinical trials.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 1, p. 74, doi. 10.1002/pst.429
- By:
- Publication type:
- Article